Peptides for muscle growth

Peptides for muscle growth are short amino-acid chains that act on the signals governing muscle protein synthesis, repair, and body composition. Most work on the growth hormone (GH) axis — stimulating the pituitary to release more of the body's own growth hormone, which raises insulin-like growth factor 1 (IGF-1). Others target IGF-1 signaling directly, the myostatin pathway that limits muscle size, or the repair of injured muscle and connective tissue.

None of them builds muscle on its own. Muscle hypertrophy is driven by resistance training, adequate protein and energy intake, and sleep. What these peptides can do is influence the hormonal environment in which that adaptation happens. The effects are real in some cases, modest in most, and poorly studied in several — which is why this guide pairs every class with the strength of its evidence.

This hub covers the landscape. Each compound has its own library page, and questions about dosing, side effects, and comparisons are answered on dedicated pages linked below.

Growth hormone is released by the pituitary in pulses, most strongly during early sleep. Two hypothalamic signals control it: growth hormone releasing hormone (GHRH) switches release on, and somatostatin switches it off. Ghrelin, best known as the hunger hormone, is a third input that amplifies release through its own receptor.

Circulating GH acts on the liver and other tissues to produce IGF-1, which mediates most of GH's anabolic effects in muscle — increased protein synthesis, satellite cell activation, and tissue repair. Rising IGF-1 then feeds back to reduce GH release. That feedback loop is the key to understanding the different peptide classes: some work inside it, and some bypass it.

The detailed physiology is on our GHRH peptides and human growth hormone pages.

"Best" depends on what is being measured. Ranked by the quality of human evidence rather than by marketing claims, the picture looks like this.

Tesamorelin has the strongest clinical trial data of any GHRH analogue — two Phase III trials supporting FDA approval as Egrifta. Those trials measured visceral fat in HIV-associated lipodystrophy, not muscle growth, so the evidence is rigorous but indirect. See tesamorelin dosage for the labeled regimen.

Sermorelin was itself an FDA-approved drug (Geref) for pediatric GH deficiency. In adults, small studies show it raises GH and IGF-1, with modest and inconsistent effects on body composition. It is the most conservative, physiological option in the class.

Ipamorelin and the CJC-1295 + ipamorelin combination are among the most discussed growth hormone peptides. Their pharmacology is well characterized, but their regulatory positions differ: ipamorelin is listed in Category 1 on the tracker, while CJC-1295 is not on it and has no established 503A eligibility; long-term controlled outcome data are limited. What the evidence does and does not show is laid out in CJC-1295 / ipamorelin body composition data.

MK-677 has been studied in longer human trials than most secretagogues, including in older adults, where increases in IGF-1 and fat-free mass have been reported. Gains in lean mass have not reliably translated into gains in strength or function, and appetite and glucose effects need watching.

IGF-1 LR3 and follistatin sit at the bottom: plausible mechanisms, mostly preclinical data, and meaningful unanswered safety questions.

IGF-1 is the downstream mediator of growth hormone's anabolic effects. Acting through the IGF-1 receptor and the PI3K/Akt/mTOR pathway, it increases muscle protein synthesis and supports satellite cells, the stem cells that repair and enlarge muscle fibers. Most GH peptides raise IGF-1 indirectly. IGF-1 LR3 acts on the receptor directly and escapes the binding proteins that normally regulate IGF-1, which makes it potent — and removes the feedback that limits risk. It has no approved use and very limited human data.

Myostatin works in the opposite direction: it is a natural brake on muscle size. Animals lacking functional myostatin develop markedly greater muscle mass, which has made the pathway an attractive target. Follistatin-344 binds myostatin and related growth factors; its evidence is largely preclinical. We cover its muscle and hair applications in Follistatin-344: muscle, myostatin, and hair growth.

A separate group of peptides is discussed for muscle and connective-tissue repair rather than growth. Their role in a muscle-building context is indirect: faster recovery from injury means less lost training time.

BPC-157 has been studied mostly in animal models of tendon, ligament, muscle, and gut injury, where it appears to promote blood-vessel formation and modulate growth-factor signaling. TB-500, a fragment of thymosin beta-4, is associated with actin regulation and cell migration in repair. GHK-Cu, a copper-binding tripeptide, is studied for collagen synthesis and tissue remodeling.

The human evidence for all three is thin, and regulation has moved. At the July 2026 PCAC meeting the FDA proposed that BPC-157 and TB-500 not be added to the 503A bulks list — see BPC-157 and the FDA 503A decision and TB-500 and the FDA 503A decision. GHK-Cu is scheduled for PCAC review before the end of February 2027. Check the FDA peptide status tracker for current status.

For body recomposition during reduced training, AOD-9604 is discussed for fat metabolism rather than muscle, and growth hormone peptides for fat loss covers how GH peptides are used to preserve lean mass during weight loss.

Regulatory status differs sharply across this group. Tesamorelin and somatropin are FDA-approved drugs for specific indications. Sermorelin, ipamorelin, and MK-677 are listed in Category 1 (under evaluation) for 503A compounding on our FDA peptide status tracker. IGF-1 LR3, GHRP-2, and GHRP-6 are not FDA-approved and do not appear on the tracker, so compounding eligibility should be confirmed before any protocol is considered.

Newtropin does not prescribe or compound. We connect licensed providers with a licensed 503A compounding partner. Practices building a performance or body-composition program can review our muscle and performance catalog for practices or start at For Providers.